Drug General Information
Drug ID	D00MXN
Former ID	DIB012116
Drug Name	MK-3207
Drug Type	Small molecular drug
Indication	Migraine [ICD9: 346; ICD10:G43]		Phase 2	[522371]
Company	Merck & Co Inc
Structure		Download 2D MOL 3D MOL
Formula	C31H30ClF2N5O3
Canonical SMILES	C12(CCCC1)NC[C@H](N(C2=O)CC(=O)Nc1cc2c(cc1)C[C@@]1(C(=O<br />)Nc3c1cccn3)C2)c1cc(cc(c1)F)F
PubChem Compound ID	49867927
Target and Pathway
Target(s)	Calcitoningene-related peptide type 1 receptor	Target Info	Antagonist	[530631]
KEGG Pathway	Neuroactive ligand-receptor interaction
	Vascular smooth muscle contraction
Reactome	G alpha (s) signalling events
	Calcitonin-like ligand receptors
WikiPathways	GPCRs, Class B Secretin-like
	Endothelin Pathways
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 522371	ClinicalTrials.gov (NCT00712725) MK3207 for Treatment of Acute Migraines (3207-005). U.S. National Institutes of Health.
Ref 530631	J Pharmacol Exp Ther. 2010 Apr;333(1):152-60. Epub 2010 Jan 11.Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.